دورية أكاديمية
Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia–a prospective study from CCCG-BNHL-2015
| العنوان: | Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia–a prospective study from CCCG-BNHL-2015 |
|---|---|
| المؤلفون: | Jiajia Dong, Zhou Xu, Xia Guo, Fanghua Ye, Chenying Fan, Ju Gao, Yijin Gao, Liangchun Yang |
| المصدر: | Heliyon, Vol 10, Iss 5, Pp e27305- (2024) |
| بيانات النشر: | Elsevier, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Science (General) LCC:Social sciences (General) |
| مصطلحات موضوعية: | Rituximab, Mature B-Cell lymphoma, Immune status, Side effect, Pediatrics, Science (General), Q1-390, Social sciences (General), H1-99 |
| الوصف: | Background: Limited research has been conducted on the impact of rituximab on immune function and the incidence of side effects in children undergoing combination chemotherapy for aggressive mature B-cell lymphoma/leukemia. Methods: Clinical data from 85 patients with primary pediatric aggressive mature B-cell lymphoma/leukemia, treated according to the Chinese Children's Cancer Group (CCCG)-mature B-cell non-Hodgkin lymphoma (BNHL)-2015 protocol from June 1, 2015, to December 1, 2022, were collected from three tertiary medical centers in China. Patients with pre-existing malignancies or primary immune deficiencies (PIDs) were excluded. Results: Between June 1, 2015, and December 1, 2022, 85 patients (65 [76.5%] boys and 20[23.5%] girls; mean age, 6.95 years) were enrolled, and immune data at baseline during follow-up were analyzed. At the end of chemotherapy, a higher proportion of patients in the R4 group exhibited a decrease in peripheral blood CD3− CD19+ B cells (20[100%] of 20 vs 13[47.8%] of 18, p = 0.04), CD3+ T cells (21[91.3%] of 23 vs 14[60.9%] of 23, p = 0.016), and serum IgM (14[60.9%] of 23 vs 4[17.4%] of 23, p = 0.003) compared to the R3 group. However, these differences were no longer statistically significant six months after chemotherapy administration. The combination of rituximab with AA was associated with a higher incidence of significant thrombocytopenia (49[81.7%] of 60 vs 29[52.7%] of 55, p = 0.001) and infection (35[58.3%] of 60 vs 17[30.9%] of 55, p = 0.003) compared to AA alone. Furthermore, the combination of rituximab with BB was linked to a higher incidence of significant thrombocytopenia (32[52.5%] of 61 vs 31[31.0%] of 100, p = 0.007) compared to BB alone. Conclusions: While the effects of rituximab in combination with intense chemotherapy for childhood aggressive mature B-cell lymphoma/leukemia on children's immune function generally recovers within six months it may still prolong the recovery from immunoglobulinemia, posing a risk of secondary infections. Further studies are required to identify children with potential primary immunodeficiencies. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2405-8440 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S240584402403336X; https://doaj.org/toc/2405-8440 |
| DOI: | 10.1016/j.heliyon.2024.e27305 |
| URL الوصول: | https://doaj.org/article/4754c31ca49b4a87832e0bae6c2b07df |
| رقم الأكسشن: | edsdoj.4754c31ca49b4a87832e0bae6c2b07df |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24058440 |
|---|---|
| DOI: | 10.1016/j.heliyon.2024.e27305 |